Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
November 14, 2014 at 09:35 pm
Share
Arno Therapeutics, Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net income of $0.160 million, or $0.01 per diluted share against net loss of $3.679 million, or $0.75 per diluted share a year ago. Loss from operations was $5.675 million against $3.786 million a year ago. Adjusted net loss was $4.551 million or $0.22 per basic share against net loss of $3.611 million, or $0.73 per basic share a year ago.
For the nine months, the company reported net income of $3.208 million, or $0.13 per diluted share against net loss of $15.918 million, or $3.34 per diluted share a year ago. Loss from operations was $17.603 million against $11.041 million a year ago. Adjusted net loss was $14.068 million or $0.69 per basic share against net loss of $9.671 million, or $2.04 per basic share a year ago.
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
ARNO THERAPEUTICS, INC. 
